Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Acute lymphoblastic leukemia


Other Names for this Disease
  • Acute lymphocytic leukemia
  • ALL
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment


Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Acute lymphoblastic leukemia. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Nelarabine
Trade Name
(Manufacturer Name)
Arranon®
(GlaxoSmithKline)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Clofarabine
Trade Name
(Manufacturer Name)
Clolar®
(Genzyme Corporation)
Indication
The FDA has approved this product to be used in this manner.
Treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Buffered intrathecal electrolyte/dextrose injection
Trade Name
(Manufacturer Name)
Elliotts B Solution
(QOL Medical, LLC)
Indication
The FDA has approved this product to be used in this manner.
For the intrathecal administration of methotrexate and cytarabine for the prevention or treatment of meningeal leukemia and lymphocytic lymphoma.
More Information about this product Drug Information Portal

Generic Name Erwinia L-Asparaginase
Trade Name
(Manufacturer Name)
Erwinase
(EUSA Pharma, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. Coli-derived asparaginase.
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Imatinib mesylate
Trade Name
(Manufacturer Name)
Gleevec®
Indication
The FDA has approved this product to be used in this manner.
Treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)
More Information about this product Drug Information Portal

Generic Name Ponatinib
Trade Name
(Manufacturer Name)
Iclusig
(ARIAD Pharmaceuticals Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
More Information about this product Drug Information Portal

Generic Name Vincristine sulfate liposome injection
Trade Name
(Manufacturer Name)
Marqibo
(Talon Therapeutics, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.
More Information about this product Drug Information Portal

Generic Name Pegaspargase
Trade Name
(Manufacturer Name)
Oncaspar®
(Enzon, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Combination chemotherapy for the treatment of patients with acute lymphoblastic leukemia who are hypersensitive to native forms of L-asparaginase.
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Dasatinib
Trade Name
(Manufacturer Name)
Sprycel®
(Bristol-Myers Squibb Company)
Indication
The FDA has approved this product to be used in this manner.
Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy
More Information about this product Drug Information Portal